Healthcare provider profile · identity verified

Babatunde Carew, MD

Internal Medicine · NASHVILLE, TN · NPI 1801359013

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	240	64
Amlodipine Besylate	Amlodipine Besylate	116	35
Rosuvastatin Calcium	Rosuvastatin Calcium	114	35
Omeprazole	Omeprazole	102	29
Losartan Potassium	Losartan Potassium	74	24
Gabapentin	Gabapentin	71	23
Carvedilol	Carvedilol	70	14
Ozempic	Semaglutide	69	12
Lisinopril	Lisinopril	66	18
Levothyroxine Sodium	Levothyroxine Sodium	65	22
Tamsulosin Hcl	Tamsulosin Hcl	60	21
Hydrochlorothiazide	Hydrochlorothiazide	57	15
Mounjaro	Tirzepatide	55	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	54	suppressed
Trazodone Hcl	Trazodone Hcl	52	15
Bupropion Xl	Bupropion Hcl	49	suppressed
Metformin Hcl	Metformin Hcl	49	15
Fluticasone Propionate	Fluticasone Propionate	45	13
Nifedipine Er	Nifedipine	45	11
Citalopram Hbr	Citalopram Hydrobromide	43	11
Furosemide	Furosemide	43	17
Meloxicam	Meloxicam	42	18
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	41	suppressed
Simvastatin	Simvastatin	41	12
Buspirone Hcl	Buspirone Hcl	39	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	39	12
Albuterol Sulfate Hfa	Albuterol Sulfate	38	12
Duloxetine Hcl	Duloxetine Hcl	38	suppressed
Allopurinol	Allopurinol	37	11
Jardiance	Empagliflozin	37	11
Escitalopram Oxalate	Escitalopram Oxalate	34	suppressed
Montelukast Sodium	Montelukast Sodium	34	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	32	suppressed
Pregabalin	Pregabalin	31	suppressed
Metformin Hcl Er	Metformin Hcl	27	suppressed
Diclofenac Sodium	Diclofenac Sodium	26	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	26	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	26	suppressed
Linzess	Linaclotide	23	suppressed
Metoprolol Succinate	Metoprolol Succinate	23	suppressed
Synthroid	Levothyroxine Sodium	23	suppressed
Spironolactone	Spironolactone	22	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	22	suppressed
Tramadol Hcl	Tramadol Hcl	21	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	18	suppressed
Atenolol	Atenolol	18	suppressed
Famotidine	Famotidine	18	suppressed
Ondansetron Odt	Ondansetron	18	suppressed
Spiriva Respimat	Tiotropium Bromide	18	suppressed
Levetiracetam	Levetiracetam	17	suppressed
Olmesartan-Amlodipine-Hctz	Olmesartan/Amlodipin/Hcthiazid	17	suppressed
Alendronate Sodium	Alendronate Sodium	16	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Breyna	Budesonide/Formoterol Fumarate	16	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	16	suppressed
Lidocaine	Lidocaine	16	suppressed
Repatha Sureclick	Evolocumab	16	suppressed
Finasteride	Finasteride	15	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	15	suppressed
Sertraline Hcl	Sertraline Hcl	15	suppressed
Alprazolam	Alprazolam	14	suppressed
Glipizide Er	Glipizide	14	suppressed
Oxycodone Hcl	Oxycodone Hcl	14	suppressed
Potassium Chloride	Potassium Chloride	14	suppressed
Pravastatin Sodium	Pravastatin Sodium	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Clopidogrel	Clopidogrel Bisulfate	13	suppressed
Glipizide	Glipizide	13	suppressed
Propranolol Hcl Er	Propranolol Hcl	13	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Lactulose	Lactulose	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Telmisartan	Telmisartan	12	suppressed
Baclofen	Baclofen	11	suppressed
Colchicine	Colchicine	11	suppressed
Divalproex Sodium	Divalproex Sodium	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error